Author:
Marx Richard,Lee Jaeweon,Svirkin Yuri,Yoon Seongkyu,Landrau Nelson,Abul Kaisar Md,Qin Bin,Park Jin H.,Alam Khondoker,Kozak Darby,Wang Yan,Xu Xiaoming,Zheng Jiwen,Rivnay Benjamin
Reference47 articles.
1. Development, characterization, efficacy and mode of action of ambisome, a unilamellar liposomal formulation of amphotericin B;Adler-moore;J. Liposome Res.,1993
2. Tissue pharmacokinetics and pharmacodynamics of Am Bisome® (L-AmBis) in uninfected and infected animals and their effects on dosing regimens;Adler-Moore;J. Liposome Res.,2017
3. Adler-Moore, J., 1994. AmBisome targeting to fungal infections. Bone Marrow Transplant 14 Suppl 5, S3-7.
4. Activity and kinetics of dissociation and transfer of amphotericin B from a novel delivery form;Baas;AAPS PharmSci.,1999
5. Lipid-based amphotericin B formulations: from animals to man;Bekersky;Pharm. Sci. Technol. Today,1999